Evaluating Micropulse Laser Treatment for Central Serous Chorioretinopathy
Official title: Central Serous Chorioretinopathy and Micropulse Laser Treatment: Evaluation of Morphological and Functional Recovery
Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06346405 · Data updated 2026-11-12
This study is testing if a special laser treatment can help people with central serous chorioretinopathy who haven't improved with other medications.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Roma, R) |
| Status | Recruiting |
| Started | May 31, 2023 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2027 |
| Registry record updated | September 23, 2025 |
| Trial ID | NCT06346405 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a diagnosis of central serous chorioretinopathy who have not responded to previous conservative treatments.
✕Probably not a fit
Patients with previous retinal treatments for CSC or other significant ocular diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess changes in the choroidal and choriocapillaris layers in patients diagnosed with central serous chorioretinopathy (CSC) who have not responded to conservative treatments with Acetazolamide and/or Eplerenone. Participants will have experienced foveal serous retinal detachment for at least six months and will undergo subthreshold micropulse laser treatment. The study will focus on understanding the effectiveness of this laser treatment in improving the condition after conservative therapy has failed.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with persistent central serous chorioretinopathy.
How similar studies have gone: While there is limited data on the specific use of micropulse laser treatment for CSC, similar laser treatments have shown promise in other retinal conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months. * Foveal serous retinal detachment for at least 6 months. * Minimum age of 18 years old at the screening time * Reading and comprehension skills of informed consent Exclusion Criteria: * Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone * No diffuse retinal epitheliopathy * Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization * Not controlled glaucoma with eyedrops, or advanced glaucoma * Myopia or hypermetropia greater than 6 diopters * Opacities of dioptric media * Low quality of optical coherence tomography (OCT) and OCT-Angiography scans * Low quality images of Fluorescein angiography and indocyanine green angiography * No written consensus signed.
Where it's running
-
Fondazione Policlinico Agostino Gemelli, IRCCS
Roma, R, Italy Recruiting
Study contacts
- Study coordinator: Maria Cristina Savastano, MD, PhD
- Email: mariacristinasavastano@policlinicogemelli.it
- Phone: (+39)063015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating the link between gut bacteria and central serous chorioretinopathy
This study is testing if the bacteria in our gut are connected to central serous chorioretinopathy and whether taking Bifidobacterium supplements can help improve vision and gut health in people with this eye condition.
-
Evaluating blood flow in rare eye diseases using advanced imaging
This study is trying to see how blood flow in the eye is different in people with rare eye diseases compared to healthy individuals using a new imaging technique.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
-
Ophthalmic Artery Doppler to predict labor problems before induction
This study tests whether measuring the ophthalmic artery Doppler in pregnant people at term who are being induced can help predict intrapartum fetal distress.
-
GCP-R3 Practice Survey for Italian Clinical Researchers
Researchers in Italy are taking a web survey to see how well they understand and apply GCP E6(R3) and to identify barriers and training needs.
-
Longitudinal profiling of plasma-derived glial extracellular vesicles in Alzheimer's disease
This study tests whether plasma glial extracellular vesicles and neuroinflammation biomarkers change over time across the Alzheimer’s disease spectrum and whether these signals relate to amyloid, tau, and neurodegeneration, with an additional step of exposing healthy iPSC-derived neurons to vesicles to see potential ne
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.